Market Place
Sourcing Support
IRLAB to Present at ABGSC Investor Days on December 4, 2024
29 Nov 2024 //
ACCESSWIRE
IRLAB to Present at Redeye Technology & Life Science Day Dec 3, 2024
27 Nov 2024 //
ACCESSWIRE
IRLAB Appoints Nomination Committee for 2025 Annual Meeting
21 Nov 2024 //
ACCESSWIRE
IRLAB to Present at BioStock Life Science Summit 2024
13 Nov 2024 //
ACCESSWIRE
IRLAB Publishes Interim Report for Jan-Sept 2024 Period
30 Oct 2024 //
ACCESSWIRE
IRLAB Reports Progress Ahead of Mesdopetam Phase III Program
29 Oct 2024 //
ACCESSWIRE
IRLAB Invites Q3 2024 Report Presentation and Webcast
28 Oct 2024 //
ACCESSWIRE
IRLAB Presents at Redeye Neurology Theme Event
18 Oct 2024 //
ACCESSWIRE
IRLAB Receives Milestone of 2.5M For IRL757 Ph I Study in Older Adult
08 Oct 2024 //
ACCESSWIRE
IRLAB Reports Positive Phase I Data For Drug Candidate IRL757
03 Oct 2024 //
ACCESSWIRE
IRLAB Granted Patent For Pirepemat Expanding Patent Protection In The US
18 Sep 2024 //
ACCESSWIRE
IRLAB Participates in Pareto Securities` 15th Annual Healthcare Conference
13 Sep 2024 //
ACCESSWIRE
IRLAB Joins `Investing In Life Science` Event
06 Sep 2024 //
ACCESSWIRE
IRLAB Publishes Interim Report for the Period January-June 2024
10 Jul 2024 //
ACCESSWIRE
IRLAB: Invitation to the Interim Report for Q2 2024 Presentation and Webcast
08 Jul 2024 //
ACCESSWIRE
IRLAB`s Phase IIb Study Of Pirepemat Proceeds After Positive Safety Review
02 Jul 2024 //
ACCESSWIRE
IRLAB Presents at Redeye Growth Day 30 May
28 May 2024 //
ACCESSWIRE
Irlab Sek 25M Loan Drawn: Liquidity Strengthened From Secured Facility
23 May 2024 //
ACCESSWIRE
IRLAB Doses First Patient In IRL757 Phase 1 Trial
22 May 2024 //
ACCESSWIRE
Report from the Annual General Meeting 2024 of IRLAB Therapeutics AB
22 May 2024 //
ACCESSWIRE
IRLAB Broadcasts the Annual General Meeting Live
22 May 2024 //
ACCESSWIRE
IRLAB Presents at ABGSC Investor Days
21 May 2024 //
ACCESSWIRE
IRLAB Publishes Interim Eeport for the Period January-March 2024
08 May 2024 //
ACCESSWIRE
IRLAB Collaborating On IRL757 For Apathy Treatment
07 May 2024 //
ACCESSWIRE
IRLAB Invites To Q1 2024 Interim Report Presentation, Webcast
06 May 2024 //
ACCESSWIRE
IRLAB Gets Swedish Approval For IRL757 Phase 1 Study
06 May 2024 //
ACCESSWIRE
IRLAB publishes Annual Report for 2023
29 Apr 2024 //
ACCESSWIRE
IRLAB To Present At Redeye Investor Forum
15 Apr 2024 //
ACCESSWIRE
IRLAB Receives End-of-Ph 2 Meeting Confirming Alignment with the FDA
22 Mar 2024 //
ACCESSWIRE
IRLAB’s Mesdopetam Displays Antipsychotic Properties in an Adv of PD`Psychosis
19 Mar 2024 //
ACCESSWIRE
IRLAB to Present at Life Science-dagen in Gothenburg and have a Fireside Chat
29 Feb 2024 //
ACCESSWIRE
IRLAB to Present at the Bayes@Lund 2024 Conference in Lund, Sweden on March 7
27 Feb 2024 //
ACCESSWIRE
IRLAB to Present Clinical and Preclinical Data at the AD/PD(TM) 2024
27 Feb 2024 //
ACCESSWIRE
IRLAB Publishes Year-end Report for the Period January-December 2023
07 Feb 2024 //
ACCESSWIRE
IRLAB’s Phase IIb Study with Pirepemat - React-PD - Provides New Insights
06 Feb 2024 //
ACCESSWIRE
IRLAB is Granted an Meeting with the FDA for Ph III-Ready Mesdopetam Program
03 Jan 2024 //
ACCESSWIRE
IRLAB Extends CEO Appointment
27 Dec 2023 //
ACCESSWIRE
IRLAB Increases its Liquidity with a Loan Facility of Up to SEK 55 Million
22 Dec 2023 //
ACCESSWIRE
IRLAB Receives Grant to Support Development of IRL757
21 Dec 2023 //
ACCESSWIRE
IRLAB’s Drug Candidate IRL757 is Phase I Ready
20 Dec 2023 //
ACCESSWIRE
IRLAB Submits Request for Meeting with the FDA for Mesdopetam Program
18 Dec 2023 //
ACCESSWIRE
IRLAB is Granted Additional Patent for Drug Candidate Pirepemat
12 Dec 2023 //
ACCESSWIRE
IRLAB to present at SEB Annual Healthcare Seminar on November 23, 2023
21 Nov 2023 //
ACCESSWIRE
IRLAB to Present at ABGSC Investor Days on November 22, 2023
20 Nov 2023 //
ACCESSWIRE
IRLAB to present at Redeye Life Science Day on November 23, 2023
20 Nov 2023 //
ACCESSWIRE
Nomination Committee Appointed for IRLAB’s Annual General Meeting 2024
07 Nov 2023 //
ACCESSWIRE
IRLAB publishes interim report for the period January-September 2023
25 Oct 2023 //
ACCESSWIRE
IRLAB to Present at BioStock Life Science Fall Summit on October 26, 2023
24 Oct 2023 //
ACCESSWIRE
IRLAB: Invitation to the Interim Report for Q3 2023 Presentation and Webcast
19 Oct 2023 //
ACCESSWIRE
IRLAB Shares Invitation to Capital Markets Day on October 17, 2023
11 Oct 2023 //
ACCESSWIRE
IRLAB Signs Phase III Regulatory US Consultants to Support Preparation
10 Oct 2023 //
ACCESSWIRE
IRLAB to present at Redeye Neurology Theme Event on October 11, 2023
10 Oct 2023 //
ACCESSWIRE
Save the date: IRLAB holds Capital Markets Day on October 17, 2023
08 Sep 2023 //
ACCESSWIRE
IRLAB: Invitation to the interim report for Q2 2023 presentation and webcast
23 Aug 2023 //
ACCESSWIRE
IRLAB Provides Update on Mesdopetam`s Phase IIb Study Data
21 Aug 2023 //
ACCESSWIRE
IRLAB Secures Full Ownership of the Mesdopetam Project
21 Aug 2023 //
ACCESSWIRE
IRLAB’s Phase IIb Study with Pirepemat Passes DSMB Safety Review
17 Jul 2023 //
ACCESSWIRE
IRLAB to Present Data from the Phase IIb Study of Mesdopetam in PD-LIDs
20 Jun 2023 //
ACCESSWIRE
IRLAB to Present at the Scientific Conference XIV Triennial Meeting
13 Jun 2023 //
ACCESSWIRE
IRLAB to present at Redeye Growth Day 2023 in Stockholm on June 1, 2023
01 Jun 2023 //
ACCESSWIRE
